Clinical Trials Logo

Clinical Trial Summary

This study evaluated the safety, efficacy and clinical benefit of BGB-3111 (zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.


Clinical Trial Description

This open-label, randomized study compared the efficacy and safety of the Bruton's Tyrosine Kinase (BTK) inhibitors BGB-3111 and ibrutinib in participants with Waldenström's Macroglobulinemia who require therapy. Participants had baseline bone marrow samples assayed for sequencing of the MYD88 gene. 201 participants with the MYD88 mutation were enrolled and randomized to receive 160 mg BGB-3111 orally twice per day (PO BID) (treatment Arm A) or to receive 420mg ibrutinib orally once per day (PO QD) (treatment Arm B) until disease progression or unacceptable toxicity. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03053440
Study type Interventional
Source BeiGene
Contact
Status Completed
Phase Phase 3
Start date January 25, 2017
Completion date June 21, 2022

See also
  Status Clinical Trial Phase
Completed NCT00398710 - A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia Phase 2
Completed NCT01788020 - Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Phase 3
Recruiting NCT03697356 - R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia Phase 2
Completed NCT02165397 - Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Phase 3
Recruiting NCT05979948 - A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia Phase 2
Recruiting NCT05326308 - Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma